In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells

Santana‑Bejarano,Uriel   Francisco; Bobadilla‑Morales,Lucina; Mendoza‑Maldonado,Lucero; Torres‑Anguiano,Elizabeth; Brukman‑Jiménez,Sinhue   Alejandro; Barba‑Barba,Cesar   Cenobio; Corona‑Rivera,Jorge   Román; Corona‑Rivera,Alfredo

doi:10.3892/ol.2019.10204

In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells

Authors:
- Uriel Francisco Santana‑Bejarano
- Lucina Bobadilla‑Morales
- Lucero Mendoza‑Maldonado
- Elizabeth Torres‑Anguiano
- Sinhue Alejandro Brukman‑Jiménez
- Cesar Cenobio Barba‑Barba
- Jorge Román Corona‑Rivera
- Alfredo Corona‑Rivera
View Affiliations

Affiliations: Cytogenetics and Genomics Laboratory, Human Genetics Institute ‘Dr. Enrique Corona Rivera’, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco 44340, México, Cytogenetics Unit, Dr. Juan I. Menchaca Civil Hospital of Guadalajara, Guadalajara, Jalisco 44340, México
Published online on: April 2, 2019 https://doi.org/10.3892/ol.2019.10204
Pages: 5224-5240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL), is characterized by the t(9;22)(q34q11) that generates the BCR‑ABL protein with uncontrolled tyrosine kinase activity. Recently, a connection between BCR‑ABL signaling with NF‑κB activation mediated by CK2 has been hypothesized. Approximately 95% of patients with Ph+ ALL have the BCR‑ABLp190 isoform, which causes aggressive leukemia with a high rate of chemotherapy resistance. Therefore, the use of compounds that could improve the efficacy of chemotherapy drugs is of particular interest. Curcumin is an active chemical in turmeric with antineoplastic potential; it regulates protein‑kinases by modulating downstream molecular pathways. The present study evaluated the effect of curcumin in combination with the chemotherapeutic drugs vincristine, imatinib and daunorubicin in the human OP‑1 cell line. Several doses of the chemotherapy drugs were examined, and the effects were evaluated following 12, 24 and 48 h of exposure. The interaction between the chemotherapy drugs and curcumin was determined by the dose‑effect curve, which generated a combination index (CI); these data were represented in isobolograms. In addition, the individual effect of each drug was compared with its effect in combination with curcumin on cell viability, apoptosis degree, NF‑κB activation and gene expression changes. The present study observed that curcumin potentiates the efficacy of vincristine and imatinib, generating an additive/synergistic effect in a dose‑ and time‑dependent manner. These combinations significantly increased the apoptosis degree, decreased the activation of NF‑κB and the expression of its regulated genes. Conversely treatment with daunorubicin + curcumin combination produced an antagonistic/additive effect in a dose‑dependent manner, and this combination significantly increased the apoptosis degree. However, this effect seems not to be associated with NF‑κB activity, as no significant changes were observed in its activation or in the expression of the genes that it regulates. The results of the present study demonstrate that curcumin may be used as an adjuvant agent for chemotherapy in patients with Ph+ ALL.

View Figures

View References

1	Thomas DA: Philadelphia chromosome positive acute lymphocytic leukemia: A new era of challenges. Hematology Am Soc Hematol Educ Program. 435–443. 2007. View Article : Google Scholar : PubMed/NCBI
2	Mishra S, Zhang B, Cunnick JM, Heisterkamp N and Groffen J: Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res. 66:5387–5393. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cilloni D and Saglio G: Molecular pathways: BCR-ABL. Clin Cancer Res. 18:930–937. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hoffman A and Baltimore D: Circuitry of nuclear factor kappaB signaling. Immunol Rev. 210:171–186. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, Kazimierczuk Z, Pinna LA and Heisterkamp N: Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia. 21:178–180. 2007. View Article : Google Scholar : PubMed/NCBI
6	Morotti A, Carrà G, Panuzzo C, Crivellaro S, Taulli R, Guerrasio A and Saglio G: Protein kinase CK2: A targetable BCR-ABL partner in philadelphia positive leukemias. Adv Hematol. 2015:6125672015. View Article : Google Scholar : PubMed/NCBI
7	Fielding AK: How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 116:3409–3417. 2010. View Article : Google Scholar : PubMed/NCBI
8	Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodrigues MA, Cabanillas F and Cantarjian H: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 106:120–127. 2006. View Article : Google Scholar : PubMed/NCBI
9	Stock W, Johnson J, Yu D, Bennett D, Sher D, Stone R, Kolitz J, Powell B, Wetzler M, Vardiman J, et al: Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): Final results from cancer and leukemia group B study 19802. Blood. 106:18332005.
10	Lyseng-Williamson K and Jarvis B: Imatinib. Drugs. 61:1765–1776. 2001. View Article : Google Scholar : PubMed/NCBI
11	Soverini I, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, et al: Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 120:1002–1009. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chattopadhyay I, Biswas K, Bandyopadhyay U and Banerjee RK: Turmeric and curcumin Biological actions and medicinal applications. Curr Sci. 87:44–50. 2004.
13	Ravindran J, Prasad S and Aggarwal BB: Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J. 11:495–510. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R and Priyadarsini K: Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta. 1780:673–679. 2008. View Article : Google Scholar : PubMed/NCBI
16	Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
17	Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 270:24995–25000. 1995. View Article : Google Scholar : PubMed/NCBI
18	Zeligs KP, Neuman MK and Annunziata CM: Molecular pathways: The balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-κB signaling for cancer treatment. Clin Cancer Res. 22:4302–4308. 2016. View Article : Google Scholar : PubMed/NCBI
19	Xia Y, Shen S and Verma I: NF-κB, an active player in human cancers. Cancer Immunol Res. 2:823–830. 2014. View Article : Google Scholar : PubMed/NCBI
20	Livak K and Schmittgen T: Analysis of relative gene expression data using realtime quantitative PCR and the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 68:621–681. 2006. View Article : Google Scholar
22	Chou J and Chou TC: Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist. 30:A2311988.
23	Rahmani AH, Al Zohairy MA, Aly SM and Khan MA: Curcumin: A potential candidate in prevention of cancer via modulation of molecular pathways. Biomed Res Int. 2014:7616082014. View Article : Google Scholar : PubMed/NCBI
24	Chen J, Wang FL and Chen WD: Modulation of apoptosis-related cell signaling pathways by curcumin as a strategy to inhibit tumor progression. Mol Biol Rep. 41:4583–4594. 2014. View Article : Google Scholar : PubMed/NCBI
25	Guo Y, Li Y, Shan Q, He G, Lin J and Gong Y: Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell Biol. 65:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
26	Gupta M, Kumar A and Dabadghao S: Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression. Am J Hematol. 71:172–176. 2002. View Article : Google Scholar : PubMed/NCBI
27	Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB and Reynolds CP: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 110:2057–2066. 2007. View Article : Google Scholar : PubMed/NCBI
28	Pimentel-Gutiérrez HJ, Bobadilla-Morales L, Barba-Barba CC, Ortega-De-La-Torre C, Sánchez-Zubieta FA, Corona-Rivera JR, González-Quezada BA, Armendáriz-Borunda JS, Silva-Cruz R and Corona-Rivera A: Curcumin potentiates the effect of chemotherapy against acute lymphoblastic leukemia cells via downregulation of NF-κB. Oncol Lett. 12:4117–4124. 2016. View Article : Google Scholar : PubMed/NCBI
29	Wang J, Wang F, Li F, Zhang W, Shen Y, Zhou D and Guo S: A multifunctional poly(curcumin) nanomedicine for dual-modal targeted delivery, intracellular responsive release, dual-drug treatment and imaging of multidrug resistant cancer cells. J Mater Chem B. 4:2954–2962. 2016. View Article : Google Scholar : PubMed/NCBI
30	Langevin PB and Atlee JL: Chemotherapeutic agents. Complications Anesth. 2:110–118. 2007. View Article : Google Scholar
31	Das K and White C: Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem. 272:14914–14920. 1997. View Article : Google Scholar : PubMed/NCBI
32	Demiray M, Sahinbas H, Atahan S, Demiray H, Selcuk D, Yildirim I and Atayoglu A: Successful treatment of c-kit-positive metastatic adenoid cystic carcinoma (ACC) with a combination of curcumin plus imatinib: A case report. Complement Ther Med. 27:108–113. 2016. View Article : Google Scholar : PubMed/NCBI